Shane Browne

Shane Browne

Auto-generated profile, based on publicly available information

Shane Browne

Tissue Engineering Research Group, Department of Anatomy & Regenerative Medicine, Royal College of Surgeons in Ireland, Dublin, Ireland

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 October 2023 in Advanced Drug Delivery Reviews
Verified
Journal Article
Open access
MMMichael G. Monaghan
Michael G. Monaghan
RBRajiv Borah
Rajiv Borah
CTCharlotte Thomsen
Charlotte Thomsen
SBShane Browne
Shane Browne
Diabetic foot ulcers (DFUs) are a devastating complication for diabetic patients that have debilitating effects and can ultimately lead to limb amputation. Healthy wounds progress through the phases of healing leading to tissue regeneration and restoration of the barrier function of the skin. In contrast, in diabetic patients dysregulation of these phases leads to chronic, non-healing wounds. In particular, unresolved inflammation in the DFU microenvironment has been identified as a key facet of chronic wounds in hyperglyceamic patients, as DFUs fail to progress beyond the inflammatory phase and towards resolution. Thus, control over and modulation of the inflammatory response is a promising therapeutic avenue for DFU treatment. This review discusses the current state-of-the art regarding control of the inflammatory response in the DFU microenvironment, with a specific focus on the development of biomaterials-based delivery strategies and their cargos to direct tissue regeneration in the DFU microenvironment.

1 July 2013 in Tissue Engineering Part A
Verified
Journal Article
Closed access
SBShane Browne
Shane Browne
Dimitrios ZeugolisDimitrios Zeugolis
Dimitrios Zeugolis
Abhay PanditAbhay Pandit
Abhay Pandit
Extracellular matrix (ECM)-based scaffolds, through their inherent bioactivity and molecular recognition signals, provide the ideal substrate for tissue engineering and regenerative applications. Collagen, the most abundant ECM protein, has proven itself to be a very versatile material with applications in many fields, including the leather and food industries, cosmetics, drug delivery, and tissue engineering. However, doubts persist about the optimal source of collagen for tissue engineering applications, given possible immunogenicity and disease transmission associated with animal sources and reduced bioactivity and availability of recombinant technologies. In this special edition, an attempt is made to elucidate the advantages of plant-derived human recombinant collagen and its applications in tissue engineering, particularly skin and wound healing. While results are promising, the widespread use of animal-derived collagen means that recombinant technologies may find applications in niche areas.

1 April 2014 in Molecular Therapy
Verified
Journal Article
Open access
PDF file
MMMichael Monaghan
Michael Monaghan
SBShane Browne
Shane Browne
KSKatja Schenke-Layland
Katja Schenke-Layland
Abhay PanditAbhay Pandit
Abhay Pandit
Directing appropriate extracellular matrix remodeling is a key aim of regenerative medicine strategies. Thus, antifibrotic interfering RNA (RNAi) therapy with exogenous microRNA (miR)-29B was proposed as a method to modulate extracellular matrix remodeling following cutaneous injury. It was hypothesized that delivery of miR-29B from a collagen scaffold will efficiently modulate the extracellular matrix remodeling response and reduce maladaptive remodeling such as aggressive deposition of collagen type I after injury. The release of RNA from the scaffold was assessed and its ability to silence collagen type I and collagen type III expression was evaluated in vitro. When primary fibroblasts were cultured with scaffolds doped with miR-29B, reduced levels of collagen type I and collagen type III mRNA expression were observed for up to 2 weeks of culture. When the scaffolds were applied to full thickness wounds in vivo, reduced wound contraction, improved collagen type III/I ratios and a significantly higher matrix metalloproteinase (MMP)-8: tissue inhibitor of metalloproteinase (TIMP)-1 ratio were detected when the scaffolds were functionalized with miR-29B. Furthermore, these effects were significantly influenced by the dose of miR-29B in the collagen scaffold (0.5 versus 5 μg). This study shows a potential of combining exogenous miRs with collagen scaffolds to improve extracellular matrix remodeling following injury.

1 May 2016 in Biomaterials
Verified
Journal Article
Closed access
AJAmit K. Jha
Amit K. Jha
KTKevin M. Tharp
Kevin M. Tharp
SBShane Browne
Shane Browne
JYJianqin Ye
Jianqin Ye
ASAndreas Stahl
Andreas Stahl
KHKevin E. Healy
Kevin E. Healy

15 May 2015 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
SBShane Browne
Shane Browne
Abhay PanditAbhay Pandit
Abhay Pandit
Inflammation plays a major role in the rejection of biomaterial implants. In addition, despite playing an important role in the early stages of wound healing, dysregulated inflammation has a negative impact on the wound healing processes. Thus, strategies to modulate excessive inflammation are needed. Through the use of biomaterials to control the release of anti-inflammatory therapeutics, increased control over inflammation is possible in a range of pathological conditions. However, the choice of biomaterial (natural or synthetic), and the form it takes (solid, hydrogel, or micro/nanoparticle) is dependent on both the cause and tissue location of inflammation. These considerations also influence the nature of the anti-inflammatory therapeutic that is incorporated into the biomaterial to be delivered. In this report, the range of biomaterials and anti-inflammatory therapeutics that have been combined will be discussed, as well as the functional benefit observed. Furthermore, we point toward future strategies in the field that will bring more efficacious anti-inflammatory therapeutics closer to realization.

1 November 2016 in International Journal of Pharmaceutics
Verified
Journal Article
Closed access
ABAlexandre A. Barros
Alexandre A. Barros
SBShane Browne
Shane Browne
COCarlos Oliveira
Carlos Oliveira
ELEstevao Lima
Estevao Lima
ADAna Rita C. Duarte
Ana Rita C. Duarte
RRRui M. Reis
Rui M. Reis